NuScale Power Makes History as the First Ever Small Modular Reactor to Receive U.S. Nuclear Regulatory Commission Design Approval
NuScale Power announced today that the U.S. Nuclear Regulatory Commission (NRC) completed Phase 6 review—the last and final phase—of the Design Certification Application (DCA) for the company’s groundbreaking small modular reactor (SMR) with the issuance of the Final Safety Evaluation Report (FSER). The FSER represents completion of the technical review and approval of the NuScale SMR design. With this final phase of NuScale’s DCA now complete, customers can proceed with plans to develop NuScale power plants with the understanding that the NRC has approved the safety aspects of the NuScale design.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200828005299/en/
An artist’s rendering of NuScale Power’s small modular nuclear reactor plant. Photo courtesy of NuScale
“This is a significant milestone not only for NuScale, but also for the entire U.S. nuclear sector and the other advanced nuclear technologies that will follow. This clearly establishes the leadership of NuScale and the U.S. in the race to bring SMRs to market. The approval of NuScale’s design is an incredible accomplishment and we would like to extend our deepest thanks to the NRC for their comprehensive review, to the U.S. Department of Energy (DOE) for its continued commitment to our successful private-public partnership to bring the country’s first SMR to market, and to the many other individuals who have dedicated countless hours to make this extraordinary moment a reality,” said NuScale Chairman and Chief Executive Officer John Hopkins. “Additionally, the cost-shared funding provided by Congress over the past several years has accelerated NuScale’s advancement through the NRC Design Certification process. This is what DOE’s SMR Program was created to do, and our success is credited to strong bipartisan support from Congress.”
NuScale’s DCA was completed in December 2016 and accepted by the NRC in March 2017. The review process demonstrated both the simplicity of NuScale’s SMR design and the thoroughness of the company’s application. As an example, during the rigorous Phase 1 review process, which included 115,000 hours spent reviewing the DCA, the NRC issued far fewer requests for additional information compared to other design certification applications. NuScale spent over $500 million, with the backing of Fluor, and over 2 million labor hours to develop the information needed to prepare its DCA application. The company also submitted 14 separate Topical Reports in addition to the over 12,000 pages for its DCA application and provided more than 2 million pages of supporting information for NRC audits.
“The NRC embraced the challenge of reviewing the first-ever small modular reactor DCA, which at the time not only marked an important milestone for NuScale, but also for the nuclear industry as a whole. NuScale appreciates the dedication, time, and effort of the NRC throughout this multi-year process, often with reviews completing ahead of schedule. As a long-time former NRC employee, including as an executive in the Office of New Reactors, I can say that this early issuance of the FSER is truly a credit to everyone at the NRC—including technical review and project staff, management, and the Commission,” said NuScale Vice President of Regulatory Affairs Tom Bergman.
NuScale continues to maintain strong program momentum toward commercialization of its SMR technology, including supply chain development, standard plant design, planning of plant delivery activities, and startup and commissioning plans. The company fields growing domestic and international customer interest from those who see the NuScale power plant as a long-term solution for providing reliable, safe, affordable, and operationally flexible carbon-free energy for diverse applications. NuScale has signed agreements with entities in the U.S., Canada, Romania, the Czech Republic, and Jordan. Similar agreements with other entities are being negotiated.
About NuScale Power
NuScale Power has developed a new modular light water reactor nuclear power plant to supply energy for electrical generation, district heating, desalination, and other process heat applications. This groundbreaking small modular reactor (SMR) design features a fully factory-fabricated NuScale Power Module™ capable of generating 60 MW of electricity using a safer, smaller, and scalable version of pressurized water reactor technology. NuScale's scalable design—a power plant can house up to 12 individual power modules—offers the benefits of carbon-free energy and reduces the financial commitments associated with gigawatt-sized nuclear facilities. The majority investor in NuScale is Fluor Corporation, a global engineering, procurement, and construction company with a 60-year history in commercial nuclear power.
NuScale is headquartered in Portland, OR and has offices in Corvallis, OR; Rockville, MD; Charlotte, NC; Richland, WA; and London, UK. Follow us on Twitter: @NuScale_Power, Facebook: NuScale Power, LLC, LinkedIn: NuScale-Power, and Instagram: nuscale_power. NuScale has a new logo, brand, and website. Watch the short video.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200828005299/en/
Contact information
Media Contact:
Diane Hughes, NuScale Vice President, Marketing & Communications
dhughes@nuscalepower.com
(C) 503-270-9329
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SK Capital Announces Definitive Agreement to Invest in Swixx BioPharma AG to Drive the Next Phase of Growth and Global Expansion15.12.2025 12:30:00 CET | Press Release
SK Capital Partners, LP (“SK Capital”), a New York-based private investment firm focused on the life sciences, specialty materials, and ingredients sectors, today announced that its affiliate has reached an agreement to invest in Swixx BioPharma AG (“Swixx” or the “Company”) to accelerate the Company’s next phase of growth and global expansion. The investment values the Company in excess of EUR €1.5 billion. Swixx is the global leader in rest-of-world pharmaceutical commercialization services dedicated to delivering innovative, life-saving medications to underserved and hard-to-reach markets. Stuart Swanson and Petr Němec, Swixx’s Co-Founders, and Jean-Michel Lespinasse and Petr Pipal, Swixx’s CEO and CFO, respectively, will all retain significant ownership stakes in Swixx as part of the transaction. Existing institutional investors HBM Healthcare Investments, a Swiss-listed investment company for the global healthcare market, and Mérieux Equity Partners, a leading healthcare-specializ
Safe Software Recognized as a Niche Player in 2025 Gartner® Magic Quadrant™ for Data Integration Tools15.12.2025 12:00:00 CET | Press Release
Safe Software, a global leader in data integration and transformation, has once again been recognized in the 2025 Gartner® Magic Quadrant™ for Data Integration Tools, marking the sixth consecutive year the company has been included in this prestigious report. Safe Software’s FME Platform has evolved well beyond its geospatial roots to become the only All-Data, Any-AI Integration Platform, empowering organizations worldwide to connect all data, applications, and AI technologies anywhere, at any scale, and with complete flexibility. With a community of more than 200,000 enthusiastic users and 25,000+ organizations in over 125 countries, FME continues to redefine data integration by delivering a no-code enterprise solution that unifies data movement, automation, and AI connectivity. “Our continued recognition reflects the trust of our customers and the innovation of our team,” said Don Murray, CEO and Co-Founder of Safe Software. “We’re proud to help organizations integrate data seamlessl
GENESIS Pharma announces a new partnership with Otsuka Pharmaceutical Europe Ltd. for the commercialization of donidalorsen for hereditary angioedema in Central and Eastern Europe15.12.2025 10:00:00 CET | Press Release
ANNOUNCEMENT FOR EUROPEAN MEDICAL & PHARMACEUTICAL TRADE MEDIA AND EUROPEAN FINANCIAL MEDIA ONLY GENESIS Pharma, a regional biopharma company focused on the commercialization of innovative medicines in Central and Eastern Europe, announces an exclusive agreementwithOtsuka Pharmaceutical Europe Ltd. (OPEL), the European operation of global healthcare company Otsuka Pharmaceutical Co., Ltd., for donidalorsen. Under the terms of the agreement, GENESIS Pharma will exclusively distribute and commercializedonidalorsen in fourteen markets: Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Greece, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. In November 2025, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for donidalorsen in the routine prevention of recurrent attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 years and older. The CHMP opinion is c
BitGo yn Sicrhau Cymeradwyaeth OCC i Drosi i Fanc Ymddiriedolaeth Genedlaethol Siartredig Ffederal13.12.2025 02:13:00 CET | Pressmeddelande
Cyhoeddodd BitGo Holdings, Inc. (“BitGo”), y cwmni seilwaith asedau digidol, heddiw fod Swyddfa Rheolwr yr Arian Cyfred (“OCC”) wedi cymeradwyo ei gais i drosi BitGo Trust Company, Inc., cwmni ymddiriedolaeth siartredig De Dakota, i fanc cenedlaethol o'r enw BitGo Bank & Trust, National Association (N.A.). Gyda chymeradwyaeth OCC heddiw o'i drosi, mae is-gwmni Cwmni Ymddiriedolaeth BitGo bellach yn gweithredu fel BitGo Bank & Trust, National Association (N.A.). Bydd BitGo Bank & Trust, N.A. yn gweithredu o dan un gyfundrefn oruchwylio ffederal unffurf, gan ei alluogi i ddarparu'r eglurder, y llywodraethiant, a'r sicrwydd rheoleiddiol y mae sefydliadau'n eu disgwyl gan ymddiriedolwr a reoleiddir yn ffederal. Mae'r gymeradwyaeth hon yn atgyfnerthu safle BitGo fel sylfaen sefydliadol ar gyfer y system ariannol fodern, gan gyfuno goruchwyliaeth ar lefel banc â'r diogelwch, y cydymffurfiaeth, a'r graddadwyedd sy'n diffinio seilwaith BitGo. O dan siarter y banc cenedlaethol, ac yn amodol ar
FIA, Formula 1 Group and All 11 Race Teams Officially Sign the Ninth Concorde Agreement, Securing Strength and Stability for the Sport in Pivotal Five-Year Agreement12.12.2025 17:10:00 CET | Press Release
The Fédération Internationale de l'Automobile (FIA), the global governing body for motor sport and the federation for mobility organisations worldwide, and Formula 1 Group, the Commercial Rights Holder, have today announced the signing of the Concorde Governance Agreement, a crucial contract defining the regulatory framework and governance terms of the FIA Formula One World Championship until 2030. This follows the announcement in March that the 2026 Commercial Concorde Agreement had been signed by all the teams and Formula 1 Group. Together, these agreements constitute the ninth Concorde Agreement, representing a major step forward in the professionalisation and global development of the sport. First introduced in 1981, the Concorde Agreements are designed to promote sporting fairness, technological innovation and operational excellence, and align all key stakeholders around a shared vision for structured governance and continued growth of the sport. Each iteration of the Concorde Agr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
